NCT03208790View on ClinicalTrials.gov

Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2017

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions
Premalignant Lesion
Interventions
DRUG

Nigella sativa buccal tablets 10mg

thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg

DRUG

Nigella sativa buccal tablets 5mg

thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg

DRUG

Placebo buccal tablets

capsules with the same color and form as the active ones but without active ingredient will be given to the patients

Trial Locations (1)

11553

Faculty of Dentistry, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT03208790 - Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions. | Biotech Hunter | Biotech Hunter